This trial is testing a new combination of drugs to treat TNBC compared to the current standard of care.
1 Primary · 9 Secondary · Reporting Duration: approximately up to 42 months
Experimental Treatment
Non-Treatment Group
924 Total Participants · 2 Treatment Groups
Primary Treatment: Capivasertib · Has Placebo Group · Phase 3
Age 18 - 130 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: